E. Hambruch

发表

Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice

M. Miyazaki, U. Deuschle, G. Schmitz, 2012, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.

U. Deuschle, T. Schlüter, C. Kremoser, 2010, Bioorganic & medicinal chemistry letters.

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

U. Deuschle, M. Trauner, P. Schwabl, 2017, Journal of hepatology.

The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine‐rich glycoprotein

U. Deuschle, C. Kremoser, O. Kinzel, 2015, International journal of cancer.

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

M. Trauner, P. Schwabl, C. Kremoser, 2021, Biomedicines.

A Novel Pex14 Protein-interacting Site of Human Pex5 Is Critical for Matrix Protein Import into Peroxisomes*♦

T. Madl, M. Sattler, W. Schliebs, 2013, The Journal of Biological Chemistry.

Pex5p, the Peroxisomal Cycling Receptor, Is a Monomeric Non-globular Protein*

W. Schliebs, M. Fransen, Jorge E Azevedo, 2005, Journal of Biological Chemistry.

Membrane Association of the Cycling Peroxisome Import Receptor Pex5p*

B. de Kruijff, W. Schliebs, Harald W. Platta, 2006, Journal of Biological Chemistry.

Membrane Association of the Cycling Peroxisome Import

W. Schliebs, B. Kruijff, Harald W. Platta, 2006 .

Membrane association of the cycling peroxisome import receptor Pex5p.

B. de Kruijff, W. Schliebs, Harald W. Platta, 2007, The Journal of biological chemistry.

On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"

C. Kremoser, O. Kinzel, E. Hambruch, 2016 .

Nonsteroidal FXR Ligands: Current Status and Clinical Applications.

C. Kremoser, O. Kinzel, N. Hambruch, 2019, Handbook of experimental pharmacology.

Distinct conformational and energetic features define the specific recognition of (di)aromatic peptide motifs by PEX14

M. Sattler, W. Schliebs, I. Antes, 2022, Biological chemistry.

Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.

U. Deuschle, T. Schlüter, C. Kremoser, 2016, Bioorganic & medicinal chemistry letters.

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

U. Deuschle, M. Trauner, P. Schwabl, 2017, Journal of hepatology.

The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats

M. Trauner, P. Schwabl, C. Kremoser, 2015 .